A long half-life reported in an anti-methamphetamine study can be misread if the measured substance is not named. In a first-in-human trial published in 2014, the 17–19-day value described an administered monoclonal antibody. It was not a measurement of methamphetamine persistence in those volunteers.
Which substance did participants receive?
Stevens and colleagues conducted a randomized, double-blind, placebo-controlled single-dose escalation study in 42 healthy volunteers. Thirty-two received intravenous ch-mAb7F9, an anti-methamphetamine antibody, at doses ranging from 0.2 to 20 mg/kg; ten received saline. Follow-up lasted 147 days. This was not a methamphetamine challenge study.
The distinction is fundamental to reading the dose units. “20 mg/kg” in this trial refers to antibody mass, not stimulant dose. Similarly, the serum pharmacokinetic assay tracked the investigational antibody. Substituting the target drug’s name for the measured analyte would change the scientific meaning of the result.
What did the pharmacokinetic findings show?
In the three highest antibody-dose groups, terminal half-life was approximately 17–19 days and distribution volume approximately 5–6 L. The authors interpreted the distribution as primarily vascular.
Persistence of a binding agent can inform the design of later studies. It does not by itself establish how long clinical benefit lasts, how much drug effect is prevented, or whether repeated stimulant exposure overcomes an antibody’s binding capacity. Those questions require exposure and efficacy measurements that this study did not provide.
Did “no serious adverse events” mean no adverse events?
No deaths, serious adverse events or adverse-event discontinuations occurred. Nevertheless, 40 of 42 participants experienced at least one adverse event during follow-up. The study did not identify a maximum tolerated dose.
An event observed after treatment is not automatically caused by treatment; conversely, absence of serious events in a small selected sample does not exclude rare risks. The useful safety description preserves event severity, investigator attribution, exposure conditions and sample size rather than replacing them with an unrestricted claim of safety.
What did the 12.5% immune-response result mean?
Four of the 32 antibody recipients developed confirmed human anti-chimeric antibody responses by study end. This response did not appear dose-related.
That denominator concerns recipients of the investigational antibody. It is not the percentage protected against methamphetamine, nor a measure of spontaneous immunity to the drug. Antibodies directed against the treatment are a different analyte and scientific question from the treatment antibody’s ability to bind methamphetamine.
Was treatment effectiveness demonstrated?
The trial’s primary purpose was single-dose safety and tolerability; pharmacokinetics and immunogenicity were additional objectives. Healthy volunteers were not an efficacy population for measuring reduced methamphetamine use, overdose outcomes or relapse prevention.
This historical trial can therefore support a statement about early human testing of a particular molecule under specified conditions. It cannot establish clinical effectiveness, current regulatory status or an individual treatment recommendation. Keeping the administered substance, measured analyte and endpoint separate prevents a promising development-stage result from becoming an unsupported therapeutic claim.
Source
Stevens MW, Henry RL, Owens SM, Schutz R, Gentry WB. First human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteers. mAbs. 2014;6(6):1649–1656. doi:10.4161/19420862.2014.976431. Full text. Phase 1 human safety and pharmacokinetic trial.